Agenus (AGEN) Total Non-Current Liabilities (2010 - 2026)
Agenus' (AGEN) quarterly Total Non-Current Liabilities came in at $15.8 million in Q1 2026, down 92.09% year-on-year from $199.4 million in Q1 2025, and up 2.21% quarter-over-quarter from $15.4 million in Q4 2025.
Agenus (AGEN) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Agenus' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 92.09% year-over-year to $15.8 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 92.09% decrease from a year earlier, with the FY2025 full-year figure at $15.4 million, down 93.16% from the prior year.
- Total Non-Current Liabilities rose to $15.8 million in Q1 2026 per AGEN's latest filing, from $15.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $454.4 million in Q2 2022 and bottomed at $15.0 million in Q3 2025.
- The 5-year median for Total Non-Current Liabilities is $290.9 million (2024), against an average of $268.6 million.
- Across the five-year window, Total Non-Current Liabilities surged 141.47% in 2022 and plunged 93.67% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $398.9 million in 2022, then dropped by 22.66% to $308.5 million in 2023, then slipped by 26.89% to $225.5 million in 2024, then plunged by 93.16% to $15.4 million in 2025, then gained by 2.21% to $15.8 million in 2026.
- Per Business Quant, the three latest AGEN Total Non-Current Liabilities figures stand at $15.8 million (Q1 2026), $15.4 million (Q4 2025), and $15.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Agenus | 184.05 Mn | 177.29 Mn | 33.74 Mn | 15.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.78 Mn |
| Dec 31, 2025 | 15.44 Mn |
| Sep 30, 2025 | 15.04 Mn |
| Jun 30, 2025 | 184.47 Mn |
| Mar 31, 2025 | 199.44 Mn |
| Dec 31, 2024 | 225.53 Mn |
| Sep 30, 2024 | 237.71 Mn |
| Jun 30, 2024 | 290.93 Mn |
| Mar 31, 2024 | 253.83 Mn |
| Dec 31, 2023 | 308.49 Mn |
| Sep 30, 2023 | 327.16 Mn |
| Jun 30, 2023 | 372.52 Mn |
| Mar 31, 2023 | 398.94 Mn |
| Dec 31, 2022 | 398.86 Mn |
| Sep 30, 2022 | 427.55 Mn |
| Jun 30, 2022 | 454.38 Mn |
| Mar 31, 2022 | 439.87 Mn |
| Dec 31, 2021 | 464.38 Mn |
| Sep 30, 2021 | 433.90 Mn |
| Jun 30, 2021 | 188.17 Mn |